Date: 20-Sep-2019

EASD Lilly, BI's Jardiance tops GLP-1s at cutting heart failure hospitalization in real-world study

BARCELONA—The GLP-1 and SGLT2 diabetes drug classes have been dueling for years now, with drugmakers gunning to produce data that give their drugs an edge. The latest from partners Boehringer Ingelheim and Eli Lilly showed their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization. Pitted against GLP-1s in a real-world data study, Jardiance pared down the risk of heart failure hospitalizations by 26%, BI and Lilly said Thursday at the European Association for the Study of Diabetes annual meeting. “We really think that is good for patients because heart failure and diabetes is really very common, and it leads to premature death and lots of costs to health systems,” Jyothis George, BI’s head of medicine for Jardiance, said.